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Abstract
Galectin-3 (gal-3) is a b-galactoside binding protein related to many tumoral aspects, e.g. angiogenesis, cell growth and
motility and resistance to cell death. Evidence has shown its upregulation upon hypoxia, a common feature in solid tumors
such as glioblastoma multiformes (GBM). This tumor presents a unique feature described as pseudopalisading cells, which
accumulate large amounts of gal-3. Tumor cells far from hypoxic/nutrient deprived areas express little, if any gal-3. Here, we
have shown that the hybrid glioma cell line, NG97ht, recapitulates GBM growth forming gal-3 positive pseudopalisades
even when cells are grafted subcutaneously in nude mice. In vitro experiments were performed exposing these cells to
conditions mimicking tumor areas that display oxygen and nutrient deprivation. Results indicated that gal-3 transcription
under hypoxic conditions requires previous protein synthesis and is triggered in a HIF-1a and NF-kB dependent manner. In
addition, a significant proportion of cells die only when exposed simultaneously to hypoxia and nutrient deprivation and
demonstrate ROS induction. Inhibition of gal-3 expression using siRNA led to protein knockdown followed by a 1.7–2.2 fold
increase in cell death. Similar results were also found in a human GBM cell line, T98G. In vivo, U87MG gal-3 knockdown cells
inoculated subcutaneously in nude mice demonstrated decreased tumor growth and increased time for tumor engraftment.
These results indicate that gal-3 protected cells from cell death under hypoxia and nutrient deprivation in vitro and that gal-
3 is a key factor in tumor growth and engraftment in hypoxic and nutrient-deprived microenvironments. Overexpression of
gal-3, thus, is part of an adaptive program leading to tumor cell survival under these stressing conditions.
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Introduction
Galectins are a family of lectins with b-galactoside binding
domains (carbohydrate recognition domains, CRDs). Fifteen
galectins have been identified so far and divided into 3 subgroups:
prototype, chimera and tandem. Gal-3 is the only galectin
belonging to the chimera subgroup and it contains one CRD
and an extended N-terminal domain [1]. It has a molecular mass
ranging from 29 to 34 kDa and seems to be involved in increased
cell motility [2], cell growth and angiogenesis [3–6], promoting
cell resistance to reactive species of nitrogen and oxygen [7] and it
is important in the formation of metastatic colonies [8].
Gal-3 plays different roles, occasionally in opposite ways,
depending on its sub-cellular localization; (i) in the nucleus, it
participates in the processing of pre-mRNA [9] and control of
expression of selected genes [10,11]; (ii) in the cytoplasm, it acts
inhibiting apoptosis [12–14]; (iii) extracellularly, it acts as a
deadhesion molecule interfering with cell-cell interactions [15],
cell-matrix interactions [16,17] and also participates in the
induction of apoptosis [18]. And, at least in part, sub-cellular
compartimentalization of gal-3 seems to be phosphorylation
dependent [4,19].
Some studies have demonstrated that gal-3 can be modulated
by hypoxia, a common feature in solid tumors [20–22]. Hypoxia
occurs when cells are deprived of oxygen due to vaso-occlusion or
deficient angiogenesis, causing also nutrient deprivation and
leading to tumor necrosis [23]. This is one of the hallmarks of
glioblastoma multiformes (GBM), a common Central Nervous
System (CNS) tumor, accompanied by the presence of pseudopa-
lisades, described as hypercellular areas around necrotic tissue
environments, which are likely composed of cells actively
migrating out the hypoxic/necrotic foci [23–25].
These pseudopalisading cells are from 5 to 50% less prolifer-
ative and from 6 to 20 times more prone to apoptosis than
adjacent cells. Some molecules are strongly involved in the biology
of pseudopalisading cells, like the hypoxia inducible factor (HIF-
1a) [24,26] and gal-3, which is found expressed specifically within
pseudopalisading cells [27] and has been widely studied in CNS
tumors [28–32]. However, the roles of gal-3 in both oxygen and
nutrient deprivation microenvironments are still unknown.
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In this work, we analyzed the impact of hypoxia and serum
deprivation on the expression pattern of gal-3 and its consequenc-
es in the survival of a hybrid human/murine glioma cell line,
NG97ht [33,34], and the human glioblastoma cell line, T98G in
vitro. Also, we analyzed the in vivo impact of gal-3 knockdown in
the tumor development of the human glioma U87MG cell line
inoculated in nude mice. Here, we have shown that gal-3
expression is part of an adaptive program that protects glioma
cells from death under hypoxia and serum deprivation and that it
is also a key factor in the tumor growth and engraftment in ill
perfused microenvironments, suggesting a protective role for gal-3
under these extreme stress conditions.
Experimental Procedures
Cell culture
The hybrid human/murine NG97ht glioblastoma cell line
[33,34] was cultured in RPMI 1640 medium containing 10–13%
fetal bovine serum (FBS) and the human glioblastoma cell lines,
U87MG (ATCC HTB-14) and T98G (ATCC CRL-1690), were
cultured in DMEM low glucose containing 10% FBS. Cell cultures
were incubated at 37uC in an atmosphere containing 95% air and
5% CO2.
Xenotransplants derived from the NG97ht cell line
NG97ht xenotransplants were induced by subcutaneous inoc-
ulation of 16106 in the flank of nude mice. These animals were
kept in sterile and specific pathogen free environments supplied
with water and barren rations ad libitum for 20 days
Tumor tissues were harvested and formalin-fixed, dehydrated
and paraffin embedded and then subjected to either routine eosin
and hematoxylin staining or immunohistochemistry.
Procedures for immunohistochesmitry for gal-3 were performed
as described previously by Neder et al. [27] using M3/38 rat anti-
gal-3 monoclonal antibody (TIB166, from ATCC), where suitable
anti-rat secondary antibodies conjugated with HRP were used. For
the identification of hypoxic areas in vivo, we used the
Hypoxyprobe-1 Kit (Chemicon International), as described by
the manufacturer. For NF-kB immunohistochemistry, the SC-109
antibody (Santa Cruz) was used for the detection of the p65
subunit, using the Superpicture reagent (Life Technologies) as a
secondary detection marker conjugated with HRP.
Hypoxia and cobaltous chloride assays
Hypoxia was achieved by subjecting cells to an air flow
composed by 95% of N2 and 5% of CO2 for 5 minutes within a
Billups-Rothenberg – Modular Incubator Chamber (Del Mar,
USA). After, the chamber was sealed. Partial pressure (p) of O2
was monitored using an oxygen sensor (PAC 3000, Dra¨eger,
Germany) throughout the experiment and hypoxia was defined as
pO2,1%.
Cobaltous chloride (CoCl2) was used as an agent capable of
mimicking hypoxia by the stabilization of HIF-1a [35,36] only for
the NG97ht cell line in a concentration of 100 mM. Cells in
normoxia were cultured under normal culture conditions as
previously described.
qRT-PCR for gal-3
NG97ht cells were cultured in triplicates in six-well plates and
exposed to either normoxia, CoCl2 and hypoxia in 13% or 1%
FBS for 3, 6, 24 and 48 h. Total RNA was extracted by TRIzol
method and cDNA was obtained using SuperScript III enzyme
(Invitrogen), as described by the manufacturer.
The qRT-PCR reactions were carried out with the following
primers: murine gal-3 (sense-59-CCT GGA GCT TAT CCT
GGT CA -39, anti-sense-59-GTC ACC ACT GAT CCC CAG
TTT-39) and b-actin (sense-59-AGA AAA TCT GGC ACC ACA
CC-39, anti-sense-59-AGA GGC GTA CAG GGA TAG CA-39).
All reactions were performed in the Rotor Gene 3000 (Corbett
Life Science) and analyzed using the Rotor Gene 6 software.
Gal-3 differential expression was determined by the Pfafll
method of analysis [37], using b-actin as normalizer gene.
Protein analysis
Cells were cultured and exposed to normoxia, CoCl2 (for
NG97ht cells) and hypoxia in complete or deprived medium for
48 h. Cells were then washed with cold PBS and protein
extractions were performed as described previously. Protein
extracts were separated by 12% SDS-PAGE, using reducing
sample buffers and the proteins were then electroblotted to PVDF
membranes. The primary antibodies used were the M3/38 rat
anti-gal-3, the B4-G2 mouse anti-caspase 7 (Biovision) and mouse
anti-b-actin (SIGMA). Suitable secondary antibodies conjugated
with peroxidase were then used.
Two-dimensional gel electrophoresis
NG97ht and U87MG cells were exposed to normoxia, CoCl2
(NG97ht) and hypoxia in 1% FBS for 48 h. Cells were then
washed with cold PBS and protein extractions were performed as
described previously.
Protein extracts were treated with acid phosphatase 100 mg/mL
in pipes buffer 40 mM pH6.0 for 30 minutes at 37uC and control
treatment was performed using only pipes buffer. Proteins were
precipitated in cold acetone three times their volume for 4 h at
-20uC and they were centrifuged at 13000 rpm for 15 minutes at
4uC and then dried at room temperature.
Proteins were then subjected to the first dimension in Immobi-
line DryStrips 3–10 (Amersham), according to the manufacturer.
Then, second dimension was performed in a 12% SDS-PAGE,
electroblotted to PVDF and incubated in the M3/38 rat anti-gal-3
as previously described. Image analysis for the quantification of
protein forms was performed using the ImageJ software.
Translation inhibition with cycloheximide
NG97ht cells were cultured in quadruplicates in six-well plates
and exposed to normoxia, CoCl2 or hypoxia in 1% FBS and to
DMSO, cycloheximide (CHX) 5 mM or 20 mM for 6 h. Then,
cells had their total RNA extracted and cDNA produced. qRT-
PCR was performed and primers used were for the murine gal-3
sequence, as previously described, and murine RPLP0 (sense-59-
TGC CAC ACT CCA TCA TCA AT-39, anti-sense-59-CGA
AGA GAC CGA ATC CCA TA-39), used as normalizer gene.
HIF inhibition with CAS 934593-90-5 and NF-kB inhibition
with dehydroxymethylepoxyquinomicin (DHMEQ)
NG97ht cells were cultured in triplicates in six-well plates and
exposed to either normoxia, CoCl2 or hypoxia in 1% FBS for 24 h
and exposed to DMSO, the HIF-1a inhibitor 10 mM (CAS
934593-90-5, Calbiochem) or DHMEQ 5 mg/mL, an NF-kB
inhibitor [38]. Then, total RNA was extracted and cDNA
obtained and analyzed as previously described. VEGF and
CCL5 gene induction was used as a control for the HIF-1a and
NF-kB inhibition, respectively. Also protein extracts were
performed and analyzed as previously described for the gal-3
detection.
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Immunofluorescence for HIF-1a
NG97ht cells were cultured in 13 mm coverslips and exposed to
normoxia, CoCl2 and hypoxia in serum-deprived medium for
48 h, then fixed in 1% paraformaldehyde and processed for the
detection of HIF-1a. Primary antibody used was the rabbit anti-
HIF-1a GTX30124 (Genetex) and the secondary antibody was the
anti-rabbit Alexa 488 (Invitrogen). Cells nuclei were stained with
DAPI and analyzed in confocal microscopy (Zeiss LSM 510
Meta/UV).
DNA content analysis by propidium iodide staining
NG97ht cells were cultured in triplicates in six-well plates,
exposed to normoxia, CoCl2 or hypoxia in complete or deprived
medium for 24, 48 and 72 h. For the evaluation of cell death, cells
were analyzed for their DNA content by propidium iodide
staining. Cells were harvested by trypsinization, fixed in ethanol
70% and analyzed by flow cytometry (FACScalibur) through the
binding of propidium iodide [39,40]. Briefly, cells were washed
twice in PBS after fixation and were incubated in 20 mg/mL of
propidium iodide, 200 mg/mL of RNAse and 0,1% v:v of Triton
X-100 in PBS for 30 minutes protected from light, then cell death
was analyzed by the evaluation of cellular DNA content by flow
cytometry (FACScalibur BD), and subsequent identification of
hypodiploid cells.
Detection of reactive oxygen species (ROS) by
diihydroethidium (DHE)
NG97ht cells were cultured in triplicates in six-well plates,
exposed to normoxia, CoCl2 or hypoxia in complete or deprived
medium for 48 h. For ROS detection, cells were incubated for 30
minutes at 37uC with DHE 5 mM diluted in medium and then
harvested by trypsinization. Cells were centrifuged for 2 mins at
2000 rpm and ressuspended in PBS and the evaluation of ROS
was performed by flow cytometry (FACScalibur BD) using the
geometric mean of the median fluorescence intensity.
Gal-3 specific siRNA and shRNA knockdown
For gal-3 siRNA knockdown assays, NG97ht cells were cultured
in triplicates in six-well plates. Cells were washed with OPTIMEM
medium (Gibco, Invitrogen) and then incubated with 100 pmols of
gal-3 siRNA (59UUU CCU GAU UAG UGC UCC ACC CGC
CGC-39; 59-GGG GGG UGG AGC ACU AAU CAG GAA A-39)
or 100 pmols of scramble siRNA with 4 ml of Lipofectamine 2000
(Invitrogen). Oligonucleotides for gal-3 silencing and scramble
oligonucleotides were purchased from IDT- Integrated DNA
Technologies (Coralville, IA). Cells were kept for 6 h in an
atmosphere with 37uC and 5% of CO2 in absence of FBS. Cells
were then exposed to normoxia, CoCl2 or hypoxia in 13% or 1%
FBS, as previously described, for 42 h. After this exposure, gal-3
mRNA and proteins were extracted and analyzed or cells were
subjected to cell death analysis as previously described.
For T98G and U87MG gal-3 shRNA knockdown, cells were
transduced with a lentivirus containing gal-3 shRNA sequence
(OpenBiosystems, pLKO-shGAL3 Cat. TRC0000029305) and
then subjected to cell selection by puromicyn (1 mg/mL for T98G
and 0.5 mg/mL for U87MG). The shRNA scramble sequence was
used as a transduction control. Gal-3 knockdown was evaluated by
western blot and by qRT-PCR using primers for the b-actin and
for the human gal-3 (sense-59 -AGA CAG TCG GTT TTC CCA
TTT -39, anti-sense-59 -ACC AGA AAT TCC CAG TTT GCT-
39). For T98G cell death analysis, cells were plated in triplicates in
six-well plates and treated for 48 h in 10% or 1% FBS in either
normoxia or hypoxia and then the DNA content was analyzed by
flow cytometry (FACScalibur BD).
For the U87MG in vivo assay, 56106 cells were inoculated in
the flank of nude mice using the scramble shRNA (n = 6) and gal-3
shRNA cells (n = 5). These animals were kept under sanitary
barrier conditions and supplied with water and barren rations ad
libitum until they had formed a tumor mass around 1 to 1.4 cm3.
Tumor sizes were measured every two to three days and were
harvested, formalin-fixed, dehydrated and paraffin embedded and
then subjected to routine eosin and hematoxylin staining.
U87MG cell growth assay
U87MG cells transduced with scramble or gal-3 shRNA were
analyzed for cell proliferation in vitro. Cells were cultured in
triplicates in six-well plates (16105 per well) and counted for every
24 h after the first 48 h for six days for comparison between these
two cells.
Animal ethical committee approval
This work was approved by the Ethical Committee for Animal
Experimentation (CEEA) (project number 0993/09, registry
number 4673) and followed the guidelines of the Brazilian Council
on Animal Care (COBEA).
Statistical analysis
All statistical analysis was performed with the GraphPad Prism
5.0 software. Differences were considered statistically significant if
the probability value was less than 0.05 and all data are presented
as mean6SEM.
Results
NG97ht cell line recapitulates glioblastoma growth in
nude mice and demonstrates accumulation of gal-3
within pseudopalisades
Based on histopathological analysis of tumor tissues, we could
observe both necrosis (Fig. 1*) and the organization of pseudopa-
lisades (Fig. 1A, arrows), as described by Grippo and coworkers
[33]. Furthermore, we showed that pseudopalisading areas are
hypoxic (Fig. 1B, arrows) due to staining of pimonidazole, and
display an intense staining for gal-3 in the cytoplasm of
pseudopalisading cells (Fig. 1C, arrows) and in scattered cells
within the tumor. Gal-3 ligands were also detected in pseudopa-
lisades (Figure S1).
NG97ht cells in hypoxia and nutrient deprivation induce
gal-3 expression and present multiple electrophoretic
forms in vitro
Oxygen deprivation was achieved by culturing cells in hypoxic
chambers (Figure S2), or alternatively mimicked through the
exposure of cells to CoCl2, an inhibitor of prolyl-hydroxylases
[35,36].
It was observed gal-3 mRNA upregulation after 24–48 h either
in complete or serum-deprived medium (Fig. 2A/B) in the
NG97ht cell line. This hybrid cell line only expresses the murine
gal-3 from its genome, since it lacks the human gal-3 gene. Protein
analysis demonstrated accumulation of gal-3 in cells exposed to
either CoCl2 or hypoxia after 48 h compared to normoxia
(Fig. 3C). Two electrophoretic forms of gal-3, ranging from
28.8 kDa to 29.7 kDa, were observed in the experiments, with
accumulation of the higher molecular weight form of gal-3.
Two-dimensional electrophoresis demonstrated five main gal-3
electrophoretic isoforms (Fig. 2D), 1 to 5 according to their
Gal-3 Protects from O2 and Serum Deprivation
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isoelectric point (IP), ranging from 8.00 to 9.33. Protein extracts
treated with acid phosphatase (AP) demonstrated decrease in
forms 2 and 3. Quantification of these different gal-3 isoforms with
the Image J software demonstrated that in hypoxia, basic isoforms
were relatively increased compared to acidic isoforms (Fig. 2E)
and that the treatment with AP decreased acidic isoforms in
normoxia compared to hypoxia, but basic isoforms displayed the
same rates of modifications in all conditions (Fig. 2F).
Also, mass spectrometry analysis of gal-3 derived from NG97ht
showed two gal-3 variants expressed in this cell line, differing in
the C-terminal domain of the protein (251Gly and 251Arg)
explaining the sister isoforms 4 and 5 (data not shown). In
addition, two-dimensional electrophoresis of protein extracts from
the U87MG cell line demonstrated IP variations ranging from 7 to
9. In normoxia, gal-3 displayed acid phosphatase-sensitive
modifications, which were less detected in cells exposed to hypoxia
(Fig. 2G). Altogether, these results indicated that, if any alterations
are observed, gal-3 seems less phosphorylated under hypoxic
conditions.
Gal-3 expression depends on de novo protein synthesis
and on HIF-1a and NF-kB in vitro when exposed to
hypoxia and nutrient deprivation
To evaluate whether gal-3 induction under CoCl2 and hypoxia
was due to factors already present in NG97ht cells prior to the
exposure to hypoxia, we treated these cells with cycloheximide, an
inhibitor of protein translation, and verified if gal-3 upregulation
was resistant to it. As observed in Fig. 3A, upon exposure to
cycloheximide, no gal-3 upregulation was observed in serum-
deprived cells in either CoCl2 or hypoxia when compared to cells
exposed to DMSO. We further evaluated the dependence of both
HIF-1a [41–44] and NF-kB [45] in nutrient and oxygen deprived
dependent gal-3 induction.
The HIF-1a inhibitor (compound CAS 934593-90-5), which
inhibits HIF-1a accumulation and gene transcription activity, led
to a decrease in gal-3 induction in cells exposed to hypoxia and
nutrient deprivation both by mRNA (Fig. 3B) and protein analysis
(Fig. 3D). The immunofluorescence for HIF-1a in NG97ht cells
demonstrated that this protein is not accumulated in the nucleus in
cells in normoxia, but only when cells are exposed to CoCl2 and
hypoxia (Fig. 3F).
To evaluate the NF-kB putative roles, we exposed NG97ht cells
to dehydroxymethylepoxyquinomicin (DHMEQ), which inhibits
NF-kB translocation to the nucleus and DNA binding, or DMSO
(as control) in normoxia, CoCl2 and hypoxia in serum-deprived
medium. Our results demonstrated that DHMEQ decreased gal-3
induction under hypoxia exposure when compared to DMSO
both in mRNA (Fig. 3C) and protein levels (Fig. 3E).
Immunohistochemistry for NF-kB in vivo in the tumor mass
originated from the inoculation of NG97ht cells in the flank of
nude mice demonstrated its accumulation in pseudopalisading
cells (Fig. 3G, arrows) both in the cytoplasm and in the cells nuclei.
Combined oxygen and serum deprivation, but not
hypoxia alone, trigger NG97ht cell death, which is
accompanied by the induction of ROS
To evaluate the cell death rates at different experimental
conditions, cell death assays with propidium iodide staining were
performed. In complete medium, cell death rates were the same in
both normoxic and hypoxic conditions (Fig. 4A), however, when
cells were exposed to oxygen and serum deprivation, increased cell
death rates were observed after 48–72 h (Fig. 4B). Regarding cells
exposed to CoCl2, we could observe increased cytotoxicity,
regardless serum concentration, in time points .24 h (Fig. 4A/
B). The detection of reactive oxygen species (ROS) (Fig. 4C)
demonstrated ROS induction in cells exposed to CoCl2 and
hypoxia both in complete or deprived medium.
Also, our studies demonstrated that DHMEQ increased cell
death rates in cells exposed to both normoxia and hypoxia in
nutrient deprivation (Fig. 4D) compared to controls exposed to
DMSO.
Caspase 7 analysis by western blot assays demonstrated
increased active caspase 7 in cells exposed to CoCl2 and hypoxia
compared to normoxia both in complete or serum-deprived
medium (Fig. 4D).
Gal-3 knockdown increases cell death in oxygen and
serum deprived cells
As shown in Fig. 5, incubation of NG97ht cells with specific gal-
3 siRNA led to a significant decrease on gal-3 both in protein
(Fig. 5A) and mRNA (Fig. 5B) levels. Inhibition of gal-3 gene
expression led to no differences in cell death rates in cells exposed
to complete medium (Fig. 5C) under either normoxic or hypoxic
Figure 1. In vivo analysis shows hypoxia and gal-3 accumula-
tion in pseudopalisades. NG97ht cells were transplanted subcuta-
neously in nude mice and tumors formed were excised and analyzed
microscopically. A. Tumors present necrotic foci (* all figures) and
pseudopalisades (arrows). HE staining. B. Tumors demonstrated hypoxic
regions (pimonidazole adducts) in pseudopalisades (brown areas,
arrows). C. Immunohistochemistry for gal-3 demonstrated pseudopali-
sades intensely stained (brown areas, arrows). Sparse cells in non-
necrotic areas around blood vessels (BV) were also positive. Scale bar
100 mm.
doi:10.1371/journal.pone.0111592.g001
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conditions. However, sensitization to cell death under exposure to
hypoxia and serum deprivation conditions is the functional
consequence of gal-3 inhibition, as shown in Fig. 5D. In addition,
gal-3 knockdown led to a significant accumulation of cells in non-
proliferating phases of the cell cycle in these treatments (Figure
S3). These findings were also observed in another human
glioblastoma cell line. In the T98G cell line, gal-3 was decreased
by shRNA knockdown both in protein (Fig. 5E) and mRNA
(Fig. 5F) levels and it was demonstrated increased cell death in
cells with gal-3 knockdown compared to control cells in hypoxia
and serum deprivation (Fig. 5G). Taken together, these data
indicate a protective role of gal-3 under extreme stress conditions
such as hypoxia and serum deprivation.
U87MG gal-3 knockdown cells display decreased tumor
growth and increased time for tumor engraftment in vivo
To analyze gal-3 possible roles in vivo, the human glioma cell
line U87MG was subjected to gal-3 knockdown by shRNA and
compared to its control. Results demonstrated both gal-3 protein
and mRNA knockdown in U87MG cells transduced with gal-3
shRNA compared to control (Fig. 6A and B). In vivo assays
inoculating these cells in the flank of nude mice displayed
decreased size and growth rates (Fig. 6C) in tumors derived from
the gal-3 shRNA cells compared to the scramble shRNA. These
differences in tumor cell proliferation were not due to differences
in cell proliferation in vitro since these cells demonstrated similar
Figure 2. Gal-3 is upregulated in hypoxia in NG97ht cells. Analysis of gal-3 by qRT-PCR and western blot in NG97ht cells exposed to normoxia,
CoCl2 and hypoxia in complete or serum-deprived medium. A/B. qRT-PCR demonstrated gal-3 mRNA upregulation after 24 h of exposure either in
complete (A) or serum-deprived medium (B ) in cells exposed to CoCl2 and hypoxia compared to normoxia. b-actin was used as normalizer.
Representative experiment performed at least in three independent assays and data are presented as mean6SEM. *p,0.05; **p,0.01; ***p,0.001. C.
Gal-3 protein accumulated after 48 h, in CoCl2 and hypoxia both in complete and serum-deprived medium. Two electrophoretic forms of gal-3,
28.8 kDa and 29.7 kDa, were observed. D. NG97ht cell protein extracts derived from cells exposed to normoxia, CoCl2 and hypoxia in deprived
medium for 48 h were submitted to treatment with acid phosphatase (AP) 100 mg/mL and analyzed by two-dimensional gel electrophoresis. Five
main forms (1 to 5) were detected in the NG97ht cell line with their isoelectric point (IP) ranging from 8.00 to 9.33 and molecular sizes from 27.5 and
29.7 kDa. Spots 4 and 5 display each two forms of same IP, but different molecular sizes. E. The quantification between isoforms 4–5 (basic) and 2–3
(acidic) demonstrated increase in the first mainly in hypoxia when compared to normoxia. F. In the treatment of the protein extracts with AP, there
was a decrease in isoforms 2 and 3 compared to control samples mainly in cells exposed to normoxia. Isoforms 4–5 did not demonstrate changes
between normoxia, CoCl2 and hypoxia. G. U87MG protein extracts derived from cells exposed to normoxia and hypoxia in deprived medium for 48 h
also demonstrated differences in two-dimensional gel electrophoresis, showing five forms (1 to 5) with IP ranging from 7 to 9 and molecular sizes
from 28.3 to 24.5 kDa. Treatment of protein extracts with AP resulted in the IP modification in gal-3 in normoxia.
doi:10.1371/journal.pone.0111592.g002
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Figure 3. Gal-3 upregulation in hypoxia depends on HIF-1a and NF-kB and is blocked by cicloheximide. A. qRT-PCR analysis of NG97ht
cells treated with cycloheximide (CHX) 5 mM and 20 mM and its control (DMSO) and in cells exposed to either normoxia, CoCl2 or hypoxia in serum-
deprived medium for 6 h demonstrated significant increase in gal-3 expression in cells exposed to CoCl2 and hypoxia compared to normoxia in the
group treated with DMSO, but not when cells were exposed to CHX. B. The exposure to HIF-1a inhibitor 10 mm (CAS 934593-90-5) demonstrated gal-
3 decreased induction by qRT-PCR in cells exposed to hypoxia, but not normoxia and CoCl2. DMSO used as control. C. The exposure to DHMEQ 5 mg/
mL, an NF-kB inhibitor, decreased gal-3 induction by qRT-PCR both in CoCl2 and hypoxia compared to normoxia after 24 h in serum-deprived
medium. DMSO used as control. D. Western blot analysis with the HIF-1ainhibitor demonstrated a slight decrease in gal-3 only in cells exposed to
hypoxia, but not normoxia and CoCl2, compared to DMSO control (experiment performed once). E. Western blot analysis also demonstrated
decreased gal-3 induction in cells treated with DHMEQ compared to DMSO in hypoxia and CoCl2 compared to normoxia after 24 h in serum-deprived
medium. F. Cells in normoxia display scattered HIF-1a (green) throughout cytoplasm, while cells exposed to CoCl2 and hypoxia display HIF-1a mainly
in cells nuclei (blue). G. In vivo, NF-kB demonstrates to be upregulated in pseudopalisading areas, which display increased gal-3 expression.
Representative experiments performed at least in three independent assays and data are presented as mean6SEM. **p,0,01; ***p,0.001.
doi:10.1371/journal.pone.0111592.g003
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proliferation rates (Fig. 6D). Also, the analysis of the tumor
engraftment rates demonstrated that gal-3 shRNA derived tumors
presented increased delay compared to scramble shRNA (Fig. 6E).
Discussion
In a previous work, we have demonstrated that gal-3
accumulated in glioma’s pseudopalisades [27], which was also
demonstrated by our results in the hybrid glioma cell line NG97ht.
Concomitant with gal-3 accumulation in pseudopalisades, scat-
tered gal-3 ligands were also found in these microenvironments
(Figure S1). These ligands could be modulating cell adhesion in
pseudopalisading cells, which would be migrating out of necrotic
foci. Galectin-3 functions, however, seem first related with tumor
cell survival in stressed microenvironments (hypoxic and serum-
deprived), such as those found in pseudopalisades.
Gal-3 upregulation in hypoxic conditions was suggested by both
transcriptomic and proteomic approaches in different in vitro
Figure 4. NG97ht cells demonstrate increased cell death only when exposed to oxygen and nutrient deprivation, which is
accompanied by the increase of reactive oxygen species and caspase-7 activation. A. Experiments performed in complete medium did not
demonstrate differences in cell death rates in cells exposed to hypoxia compared to normoxia, however, cells in CoCl2 demonstrated cell death after
48 h of exposure. B. In serum-deprived medium, longer periods of exposure (.24 h) significant cell death rates were observed in CoCl2 and hypoxia
compared to normoxia. C. ROS detection by DHE also demonstrated the increase of these molecules in cells exposed to hypoxia and CoCl2 regardless
serum concentrations and in normoxia in nutrient deprivation compared to normoxia in complete medium. D. NG97ht cells exposed to DHMEQ in
serum-deprived medium presented increased cell death in cells exposed to normoxia and hypoxia, but not CoCl2. E. Caspase 7 analysis showed
increased active caspase-7 in cells exposed do CoCl2 and hypoxia, both in complete or serum-deprived medium. Representative experiments
performed at least in three independent assays and data are presented as mean6SEM. *p,0.05; **p,0.01; *** p,0.001.
doi:10.1371/journal.pone.0111592.g004
Gal-3 Protects from O2 and Serum Deprivation
PLOS ONE | www.plosone.org 7 November 2014 | Volume 9 | Issue 11 | e111592
models [20–22]. Here, we have evaluated the impact of two
critical stressing factors of the tumor microenvironment on gal-3
expression, namely hypoxia and serum deprivation. Our results
indicate that gal-3 expression is part of a protective cellular
response to both conditions, commonly associated with decreased
protein synthesis [46]. Current evidence indicated that gal-3
participates in the endocytic process, allowing for the bending of
membranes around molecules which will be processed by cells
[47].
In one-dimensional electrophoresis, gal-3 protein presents two
distinct electrophoretic forms in NG97ht cells and these observa-
tions led to the possibility of post-translational modifications, such
as phosphorylation [48–50]. Particularly, phosphorylation at the
Ser6 is related to gal-3 anti-apoptotic effect and its export from the
nucleus to the cytoplasm [49,51]. Hill and et al. [52] had shown
that tyrosine- phosphorylation of gal-3 was upregulated in rat
colon carcinogenesis, whereas serine-phosphorylation of gal-3 was
downregulated. Our results demonstrate that phosphorylation is a
common posttranslational modification of gal-3, especially ob-
served in its most acidic isoforms in normoxia. In addition, it
seems that the NG97ht cell line expresses two different gal-3 alleles
differing in one amino acid. It is not clear what is the functional
role of this particular variant found in NG97ht cell line. Other
variants, such as the 292Arg and 292Cys variant seem clinically
relevant, as discussed elsewhere [53]. Our initial hypothesis was
that a posttranslational modification could lead to accumulation of
gal-3 in cells exposed to hypoxia. We found no evidence to back
up this idea in the experiments performed herein. Previous data
from Cao’s group had suggested that tyrosine-phosphorylation of
gal-3 would prevent its degradation by the autophagic system [54].
In different cell types, gal-3 was clearly upregulated under
hypoxia through HIF-1a dependent pathways [21,44]. Our results
indicate not only the participation of HIF-1a, but also NF-kB,
which was also upregulated in vivo in pseudopalisades. The NF-
kB family of transcription factors contribute to the regulation of
the HIF-1a gene [55,56] and it has been shown that NF-kB is also
induced upon hypoxia [57,58], contributing for gal-3 induction
and protection against cell death under oxygen and nutrient
deprivation. Nonetheless, other studies demonstrated the impor-
tance of other transcriptional factor in gal-3 induction, such as
members of the RUNX family [59–62].
However, gal-3 induction under CoCl2 seems to present some
peculiarities in comparison to hypoxia: (i) it was more sensitive to
NF-kB inhibition; and, (ii) it did not present changes with the HIF-
1ainhibitor, although HIF-1a accumulated in the cells’ nuclei,
which suggests that HIF-1a may play a minor role in gal-3
induction with CoCl2. Indeed, Olbryt and colleagues [20] had
shown that the groups of genes whose expression were modified
under either CoCl2 or low pO2 shared similarities, but were not
identical. Also, heavy metal salts such as NiCl2 and CoCl2 may
activate NF-kB [63] through the induction of the translocation of
NF-kB p65 and also p50 into the nucleus and may enhance NF-
kB DNA binding activity.
Hypoxic conditions induce different types of cell death,
including apoptosis, as previously demonstrated in a neuroblasto-
ma cell line [64] and also in the exposure to CoCl2 in glioblastoma
cells [65]. Our results suggest a relationship between nutrient
deprivation, caspase activation, hypoxia and ROS increase in the
induction of cell death in the cells studied herein, which could be
induced by the decoupling of the mitochondrial respiratory chain
Figure 5. Gal-3 knockdown sensitizes cells to cell death in oxygen and nutrient deprivation in the NG97ht cell line. Analysis of NG97ht
cells incubated with specific gal-3 siRNA or scramble siRNA for 6 h and then exposed to either normoxia (N), CoCl2 (C) or hypoxia (H) in complete or
serum-deprived medium for additional 42 h. A. Protein analysis demonstrated gal-3 knockdown in each experimental condition. Gal-3 knockdown
was calculated relatively to its b-actin control. B. In addition, gal-3 mRNA was evaluated and qRT-PCR demonstrated significant knockdown upon
treatment with specific siRNA compared to scramble siRNA. C. Analysis of hypodiploid cells demonstrated no differences in cell death rates in cells
exposed to high serum concentrations, regardless the levels of gal-3 expression. D. Upon serum-deprivation, cells were sensitized to cell death in
hypoxic conditions. Sensitization was much more pronounced upon knockdown of gal-3, as compared to cells transfected with scramble siRNA. T98G
cells transduced with gal-3 shRNA demonstrated decreased gal-3 protein by western blot (E) and mRNA by qRT-PCR (F ) compared to scramble
shRNA. Gal-3 knockdown was calculated relatively to its b-actin control. F. Analysis of hypodiploid cells demonstrated increased cell death in cells
transduced with gal-3 shRNA compared to cells transduced with scramble shRNA when exposed both to hypoxia or hypoxia and serum-deprivation.
Representative experiment performed at least in three independent assays and data are presented as mean6SEM. **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0111592.g005
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[66]. Hypoxia, however, was not sufficient to induce cell death,
since cells needed also to be nutrient-deprived, mimicking the
conditions of complete environmental stress observed in tissues
distant apart from functional vessels, which lack both oxygen and
nutrient distribution. Cell death induced by CoCl2, regardless
nutrient availability, could be due to the heavy metal cytotoxicity.
Under other conditions, however, cell death induction followed
distinct paths, as demonstrated by Steinbach and colleagues [67],
who analyzed different glioma cell lines, LN-229, U87MG and
LN-18, exposed to oxygen and glucose (and not whole nutrient)
deprivation, where cells underwent necrosis, not apoptosis. For
CoCl2, it has also been indicated its involvement in cell necrosis,
but not apoptosis [68]. Overall, studies seem to demonstrate a
different array of types of cell death regarding hypoxia.
The NF-kB inhibitor DHMEQ increased death of nutrient-
deprived cells exposed to both normoxia and hypoxia, but not to
CoCl.2. Gal-3 expression was downregulated by DHMEQ, which
was also shown to decrease the expression of other tumor survival
factors in classical Hodgkin lymphomas and induce ROS [69].
The increase of gal-3 under exposure to hypoxic conditions and
serum starvation suggests two distinct scenarios. In a first scenario,
gal-3 could be one of the inducers or sensitizers of cell death. This
scenario is usually dependent on the secretion of gal-3 and its
deposition in the extracellular matrix. We had shown that upon
infection with Trypanosoma cruzi, the causative agent of Chagas’
disease, there was an increased deposition of gal-3 in the thymic
extracellular matrix. Gal-3 increased deposition led to either
increased migration of thymocytes out of the thymus or to
increased cell death, leading to thymic atrophy [70]. Accordingly,
interaction of extracellular gal-3 with undersialylated b1 integrins
from colon carcinoma cells triggered apoptosis [18]. However, our
results indicate minor participation of extracellular gal-3 in the
induction of cell death (Figure S4). In a second scenario, gal-3
could be part of a pro-survival response triggered by hypoxia and
serum deprivation. The pro-survival role of gal-3 is often
associated with its compartmentalization to mitochondria, where
gal-3 maintains the homeostasis of this death-decision organelle
[71,72]. It seems more likely that the results presented here
corroborate with this scenario. Using siRNA/shRNA strategies,
we could achieve a reduction of the gal-3 protein level and we
could also sensitize NG97ht cells to death, thus de novo
synthesized gal-3 plays an anti-apoptotic role in cells exposed to
hypoxia and serum deprivation. Experiments with the human
T98G cell line also demonstrated that the protection granted by
gal-3 under hypoxia and nutrient deprivation, indicating this
protective role of gal-3 is a more general process.
One of the hypothesis is that gal-3 would act as a homeostatic
factor in the mitochondrial membrane [12,13,71,73], but also
there seems to be a role for gal-3 in the protection against both
reactive oxygen and nitrogen species generated in the context of
ischemia and reperfusion [7], and in the maintenance of an anti-
oxidant intracellular environment [19]. In a model of malignant
transformation of melanocytes into melanoma cells, loss of gal-3
was associated with decreased expression of glutathione-S-trans-
ferase and several other antioxidant enzymes, leading to a pro-
oxidant cellular environment [74]. Another interesting possibility
Figure 6. U87MG glioma cells transduced with gal-3 shRNA demonstrate decreased tumor size and growth. U87MG cells transduced
with gal-3 shRNA demonstrated decreased gal-3 protein by western blot (A) and mRNA by qRT-PCR (B ) compared to scramble shRNA. Gal-3
knockdown was calculated relatively to its b-actin control. C. The inoculation of U87MG gal-3 shRNA cells in the flank of nuce mice (n = 5)
demonstrated a decrease in tumor size and growth compared to the U87MG scramble shRNA (n = 6). D. The delay presented for the decrease in
tumor size and growth in the gal-3 shRNA cells was not due to a decreased tumor cell proliferation in vitro when compared to scramble shRNA cells.
E. Gal-3 knockdown cells demonstrated increased tumor free survival time compared to scramble shRNA cells. Representative experiments performed
at least in three independent assays and data are presented as mean6SEM. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0111592.g006
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was raised by the findings that gal-3 interacts directly with F(1)F(0)-
ATP synthase [75]. Recent evidence using tandem affinity
purification and mass spectrometry show gal-3 interacting with
mitochondrial proteins such as ATP5C1 and PDHX [76].
Gal-3 seems to be a key factor in tumor engraftment and
growth, as we showed here. Similar results have been shown by
other researchers in pancreatic cancer cells, for example [77].
However, opposite results were found in a prostate cancer cell line,
LNcaP, which does not express gal-3 [78]. This decreased gal-3
expression in vivo may also modulate the tumor immune response,
especially the interaction with macrophages. Dumont and
colleagues [79] have demonstrated that the supernatant from
M1 polarized macrophages, which produce TNF-a, IL-1b and
ROS, can induce tumor cell growth inhibition in vitro, and in gal-
3 knockdown cells, it can increase cell death susceptibility.
Noteworthy, when cells devoid of gal-3 are engrafted in gal-3
null mice, there is a significant delay on tumor growth [80]. Here
we have silenced gal-3 in human glioma cells and implanted the
engineered cells subcutaneously. Tumors grew at a very slow pace
and were very heterogeneous regarding gal-3 expression; small
tumors tended to be positive for gal-3, while larger tumors were
gal-3 negative, but accumulated gal-3 in the pseudopalisading
cells. As demonstrated, gal-3 expression is dynamic and it seems
especially important in early phases of tumor engraftment and in
selected microenvironments.
Gal-3 may play other roles in cells from hypoxic and serum
deprived areas, since gal-3 could also elicit cell migration and
invasion [81,82]. Altogether, gal-3 expression would determine the
fitness of cells exposed to these stressing microenvironments.
Intracellular levels would favor cell survival; upon secretion, gal-3
could act either as an autocrine or a paracrine motility factor,
favoring cellular migration out of ill perfused tissue environments.
Gal-3 could also lead to angiogenesis [3,5,6], which in turn would
restore homeostasis of hypoxic and nutrient deprived tissue
microenvironments.
In conclusion, based on these in vitro and in vivo results, we
suggest that gal-3 accumulation is part of an adaptive program
leading to tumor cell survival in hypoxic and nutrient-deprived
tumor microenvironments. Therefore, gal-3 is a potential target
for sensitizing glioma cells to death.
Supporting Information
Figure S1 Detection of gal-3 ligands in tumor pseudo-
palisades. NG97ht cells were inoculated in the flank of nude
mice and when tumors were fully grown, they were formalin fixed
and paraffin embedded for the analysis of galectin-3 ligands. A
modified gal-3, which was fused with an alkaline phosphatase
enzyme, was used in this process and results demonstrated the
availability of gal-3 ligands in pseudopalisading areas (red staining)
around necrotic areas (*). Top right figure is the negative control.
Scale bar 40 mm.
(TIF)
Figure S2 Detection of hypoxia induction in vitro by
pimonidazole. NG97ht cells were treated with pimonidazole
and exposed to normoxia, CoCl2 100 mM and hypoxia in
deprived medium for 2 h. A. Cells exposed to normoxia (A) did
not demonstrate pimonidazole adducts, which are only formed in
hypoxia under 14 mM of oxygen, or less than 10 mmHg (C). B.
Also, pimonidazole adducts were identified in cells exposed to
CoCl2 100mM. Cells nuclei were stained with DAPI, (D)
normoxia, (E) CoCl2 100 mM, (F) hypoxia (original magnification,
2006).
(TIF)
Figure S3 Gal-3 siRNA treatment increases the rate of
non-proliferating cells. Analysis of the G0-G1/S-G2-M
proportion (rate of non-proliferating cells) in NG97ht cells treated
with gal-3 siRNA or scramble siRNA and exposed to either
normoxia, CoCl2 100 mM or hypoxia in complete or deprived
medium. Cells transfected with the gal-3 siRNA demonstrated an
increase in the proportion of non-proliferating cells compared to
cells transfected with scramble siRNA in normoxia in complete
medium, and hypoxia, both in complete or serum-deprived
medium. Representative experiment of at least two independent
assays and data are presented as mean6SEM using Two-Way
ANOVA. * p,0.05; *** p,0.001.
(TIF)
Figure S4 Extracellular gal-3 plays a minor role in the
cell death induction in hypoxia. NG97ht cells were exposed
to normoxia, CoCl2 100 mM and hypoxia in serum-deprived
medium for 48 h and they were also incubated with a gal-3
binding carbohydrate, Galb1-4GlcNacb-Sp 200 mM, a control
carbohydrate, sucrose 200 mM, or no carbohydrate. Hypodiploid
cells were then counted by propidium iodide staining using a flow
cytometry. Results demonstrated a decrease in cell death in cells
exposed to Galb1-4GlcNacb-Sp in comparison to sucrose.
Representative experiment of at least three independent assays
and data are presented as mean6SEM using Two-Way ANOVA.
* p,0.05.
(TIF)
Figure S5 Gal-3 and GFAP analysis in gal-3 and
scramble shRNA U87MG tumor derived cells. U87MG
cells were transduced with an shRNA sequence for gal-3 silencing
and a control scramble shRNA and then cells were inoculated in
the flank of nude mice. After 33 days, scramble shRNA cells had
grown and demonstrated necrosis (*) with pseudopalisading cells
(arrow), which were positive for gal-3 (A). Gal-3 shRNA derived
tumors developed more slowly and reached a grown size after 64
days, demonstrating also necrosis (*) with pseudopalisading (arrow)
positive for gal-3 (B). The analysis of the gal-3 shRNA tumor
derived cells after 33 days post inoculation revealed that these
tumors upregulate and express gal-3 throughout the cells (C).
GFAP staining demonstrated the glial origin of these cells (D-E-F).
HE staining (G-H-I). Scale bar 200 mM.
(TIF)
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